Patients with ER + /HER2- early staged BC were randomized to receive: arm A) endocrine therapy alone (letrozole plus placebo), arm B) intermittent high dose ribociclib (600 mg/d) plus letrozole or arm C) continuous lower dose ribociclib (400 mg/d) plus letrozole. The gene discussed is ERBB2; the disease is breast cancer.